Femasys Inc. Common Stock (FEMY) is a publicly traded Healthcare sector company. As of May 21, 2026, FEMY trades at $0.35 with a market cap of $21.91M and a P/E ratio of -1.30. FEMY moved -2.48% today. Year to date, FEMY is -39.56%; over the trailing twelve months it is -67.48%. Its 52-week range spans $0.31 to $1.80. Analyst consensus is buy with an average price target of $1.50. Rallies surfaces FEMY's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Femasys Secures CE Mark Approval for FemHSG Catheter to Expand European Portfolio: Femasys secured CE Mark approval for its FemHSG Catheter, enabling commercial sale across Europe through its partners. The FemHSG Catheter integrates with the FemVue system for in-office ultrasound-based fertility evaluation, streamlining diagnostic workups by accommodating varying uterine cavity sizes without catheter exchange.
| Metric | Value |
|---|---|
| Price | $0.35 |
| Market Cap | $21.91M |
| P/E Ratio | -1.30 |
| EPS | $-0.27 |
| Dividend Yield | 0.00% |
| 52-Week High | $1.80 |
| 52-Week Low | $0.31 |
| Volume | 2.17K |
| Avg Volume | 0 |
| Revenue (TTM) | $2.38M |
| Net Income | $-11.88M |
| Gross Margin | 61.56% |
2 analysts cover FEMY: 0 strong buy, 2 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $1.50.